Rezaianzadeh Abbas, Jalali Maryam, Maghsoudi Ahmad, Mokhtari Ali Mohammad, Azgomi Soheil Hassanipour, Dehghani Seyedeh Leila
Research Center for Health Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Breast Dis. 2017;37(2):63-68. doi: 10.3233/BD-160244.
Breast Cancer (BC) is the most prevalent cancer and the second leading cause of cancer-related death among Iranian women. A valid estimation of the 5-year survival rate can improve the current BC treatment programs. The present study aimed to assess the 5-year survival rate through a systematic review of published studies.
A systematic search of Medline/PubMed, Scopus, and Science direct as well as Iranian databases was conducted to identify the original articles evaluating the 5-year survival rate of BC among women in Iran. Random effects model was used to estimate the pooled 5-year survival rate. The eligible articles were analyzed using the Stata software.
Our comprehensive literature search identified 11 eligible articles 2 of which were excluded due to reporting the results of a single study. The remaining 9 articles that contained 4815 women diagnosed with BC during 1991-2014 were included in the meta-analysis. The combined 5-year survival rate of BC was estimated to be 67.60%.
DISCUSSION/CONCLUSION: The survival rate of BC was relatively low in Iran compared to developed countries. Hence, more effective measures have to be taken to increase these patients' survival.
乳腺癌（BC）是伊朗女性中最常见的癌症，也是癌症相关死亡的第二大主要原因。对5年生存率进行有效的评估可以改善当前的乳腺癌治疗方案。本研究旨在通过对已发表研究的系统评价来评估5年生存率。
对Medline/PubMed、Scopus和Science direct以及伊朗数据库进行系统检索，以识别评估伊朗女性乳腺癌5年生存率的原始文章。采用随机效应模型估计合并的5年生存率。使用Stata软件对符合条件的文章进行分析。
我们全面的文献检索确定了11篇符合条件的文章，其中2篇因报告单一研究结果而被排除。其余9篇文章包含1991年至2014年期间诊断为乳腺癌的4815名女性，被纳入荟萃分析。乳腺癌的合并5年生存率估计为67.60%。
讨论/结论：与发达国家相比，伊朗乳腺癌的生存率相对较低。因此，必须采取更有效的措施来提高这些患者的生存率。
